Pharma
When four million people spend their workdays managing compliance via screenshots, spreadsheets, and Slack messages, Delve says that its AI agents can free businesses from that grind. The San Francisco-based startup, founded by MIT dropouts Karun Kaushik and Selin Kocalar, has raised a $32 million Series A led by Insight Partners at a $300 million valuation. The round comes just six months after Delve’s $3.3 million seed raise and marks a tenfold jump in valuation.
Delve’s expansion signals how quickly the market for AI-powered business automation is maturing and how high the stakes are for young companies trying to define their category.
Automating the Compliance Bottleneck
Delve emerged from a practical need. In 2023, while building an AI medical scribe, Kaushik and Kocalar were forced to complete HIPAA compliance, a process they found prohibitively manual and expensive. They pivoted, deciding to automate compliance instead. The change of direction brought them into Y Combinator and helped secure early backing from General Catalyst, Soma Capital, and others.
Now, Delve automates regulatory compliance across more than 25 frameworks, including HIPAA, SOC 2, GDPR, and ISO 27001, using AI agents that run in the background like embedded team members. These agents integrate with a company’s existing systems to collect evidence, update audit logs, monitor infrastructure, and complete required documentation.
